Seaport Therapeutics, Inc. (SPTX)
| Market Cap | 901.47M |
| Revenue (ttm) | n/a |
| Net Income | -74.88M |
| EPS | -10.04 |
| Shares Out | 53.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 910,680 |
| Open | 19.17 |
| Previous Close | 19.84 |
| Day's Range | 16.90 - 19.17 |
| 52-Week Range | 16.90 - 23.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SPTX
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research an... [Read more]
News
Seaport Therapeutics raises about $255 million in upsized IPO
Drug developer Seaport Therapeutics said on Thursday it had raised about $255 million in its upsized initial public offering in the United States.
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering.
Drug developer Seaport Therapeutics targets $912 million valuation in US IPO
Drug developer Seaport Therapeutics said on Monday it was aiming for a valuation of $912 million in its initial public offering in the United States.
Seaport Therapeutics IPO Registration Document (S-1)
Seaport Therapeutics has filed to go public with an IPO on the NASDAQ
Seaport Therapeutics IPO Registration Document (S-1)
Seaport Therapeutics has filed to go public with an IPO on the NASDAQ